Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Invuity Announces First Quarter Financial Results


Posted on: 03 May 18

SAN FRANCISCO, May 03, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announces financial results for the three months ended March 31, 2018.

Q1 2018 Highlights

  • First quarter 2018 revenue grew 5.3% to $9.5 million compared to revenue of $9.0 million in the first quarter of 2017.
  • Disposable revenue in the first quarter of 2018 grew 21.7% to $8.6 million compared to $7.0 million in the first quarter of 2017.
  • The number of accounts buying PhotonBlade® increased 23% from the fourth quarter of 2017 indicating continued strong adoption

“In the first quarter we made progress towards our near and long term goals. During the quarter, we completed an equity offering, adding $21.7 million of cash and strengthening our balance sheet. In addition, this month we have taken steps to reduce our operating expenses by implementing a restructuring designed to streamline the company and increase productivity in our commercial operations and our product development process.” said Interim Chief Executive Officer Scott Flora. “PhotonBlade continues to be an outstanding product. We saw a 23% increase in accounts ordering PhotonBlade during the quarter demonstrating continued adoption in the market. While there is still work to be done to create a balanced approach to selling our entire disposable product portfolio, I am excited by the opportunity we have in front of us and confident we can demonstrably expand the Invuity franchise.”

Financial Results

Revenue was $9.5 million in the first quarter of 2018, up 5.3% from revenue of $9.0 million in the first quarter of 2017 driven primarily by strong market acceptance of PhotonBlade.

Disposable revenue was $8.6 million in the first quarter of 2018, up 21.7% from revenue of $7.0 million in the first quarter of 2017. Disposable revenue comes from the sale of single use devices; waveguides that are attached to retractors, illuminated aspirators – both Yankauer and Frazier designs – and most recently the addition of PhotonBlade. These revenues are driven by per procedure adoption and represent the primary driver of the Company’s growth.

Gross margin for the first quarter was 69.3% compared to 76.7% for the same period in 2017. The consolidated gross margin was primarily impacted on a comparative basis by the increase in sales of PhotonBlade, which currently has a lower gross margin than other disposable products. Progress continues to be made on cost reduction programs to improve PhotonBlade margins.

Total operating expenses for the first quarter of 2018 were $17.0 million, including $3.0 million in severance and litigation expenses, compared to $17.3 million, including $1.4 million in severance and litigation expenses, in the prior year period.

The net loss for the first quarter of 2018 was $11.2 million, or $0.62 loss per share, compared to a net loss of $13.2 million, or $0.78 loss per share, for the first quarter of 2017.

The Company's balance sheet as of March 31, 2018 included total cash, cash equivalents and short-term investments of $32.6 million.

Corporate Restructuring

In May the Company implemented a corporate restructuring to streamline the business and increase productivity in the Company’s commercial operations and product development process.  It is anticipated this restructuring will reduce operating expenses by approximately $6 million on an annualized basis.

Business Outlook

For 2018 Invuity continues to expect revenue to exceed $46 million and disposable revenue to grow in excess of 25%.

Conference Call

Invuity's management will discuss the Company's financial results for the first quarter ended March 31, 2018 and provide a general business update during a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time today, May 3, 2018. To join the live call, participants may dial 1-877-556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 9299518. To listen to the live call via Invuity's website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.

About Invuity®

Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The Company’s patented Intelligent Photonics® technology delivers enhanced visualization, which facilitates surgical precision, efficiency and safety.  Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery.  Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic and general surgery. Invuity is headquartered in San Francisco, CA.

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2018 and expectations regarding our restructuring efforts, planned reduction in operating expenses, adoption of PhotonBlade, future product introductions, future sales and marketing initiatives, and market opportunities.  Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; the adequacy of the Company’s existing cash resources and funding requirements; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.

CONTACT:

Company Contact:
Jim Mackaness
Chief Financial Officer
Invuity, Inc.
415-655-2129

Investors:
Mark Klausner
Westwicke Partners
443-213-0501
irdept@invuity.com


INVUITY, INC.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
 
  Three Months Ended March 31, 
  2018  2017 
       
Revenue $9,505  $9,023 
Cost of goods sold  2,923   2,099 
Gross profit  6,582   6,924 
Operating expenses:      
Research and development  1,882   2,428 
Selling, general and administrative  15,112   14,853 
Total operating expenses  16,994   17,281 
Loss from operations  (10,412)  (10,357)
Interest expense  (775)  (487)
Interest income  56   57 
Other expense, net  (66)  (127)
Loss on extinguishment of debt     (2,303)
Net loss and comprehensive loss $(11,197) $(13,217)
Net loss per common share, basic and diluted $(0.62) $(0.78)
Weighted-average shares used to compute net loss per common share, basic and diluted  18,124,529   16,958,332 


Condensed Balance Sheets
as of March 31, 2018 and December 31, 2017
(In thousands, except share and per share amounts)
(Unaudited)
 
  March 31, December 31,
  2018
 2017
Assets      
Current assets:      
Cash and cash equivalents $29,539  $17,962 
Short-term investments  3,044   3,040 
Restricted cash - current  181   181 
Accounts receivable, net  6,257   7,421 
Inventory, net  8,729   7,436 
Prepaid expenses and other current assets  1,103   1,274 
Total current assets  48,853   37,314 
Restricted cash  727   727 
Property and equipment, net  6,989   7,169 
Other long-term assets  243   285 
Total assets $56,812  $45,495 
Liabilities and Stockholders’ Equity (Deficit)      
Current liabilities:      
Accounts payable $3,206  $3,598 
Accrued and other current liabilities  6,832   5,179 
Deferred revenue - short term  44    
Short-term debt  4,386   5,859 
Total current liabilities  14,468   14,636 
Deferred rent  2,520   2,569 
Deferred revenue - long term  80   36 
Long-term debt  29,182   29,116 
Total liabilities  46,250   46,357 
Commitments and contingencies (Note 8)      
Stockholders’ equity (deficit):      
Preferred stock, $0.001 par value—10,000,000 shares authorized at March 31, 2018 and December 31, 2017; no shares issued and outstanding at March 31, 2018 and December 31, 2017      
Common stock, $0.001 par value—100,000,000 shares authorized at March 31, 2018 and December 31, 2017; 24,023,517 and 17,179,258 shares issued and outstanding at March 31, 2018 and December 31, 2017  24   17 
Additional paid-in capital  207,869   185,255 
Accumulated deficit  (197,331)  (186,134)
Total stockholders’ equity (deficit)  10,562   (862)
Total liabilities and stockholders’ equity (deficit) $56,812  $45,495 

 

GlobeNewswire
globenewswire.com

Last updated on: 03/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.